JPWO2019146673A1 - リンパ球の製造方法 - Google Patents
リンパ球の製造方法 Download PDFInfo
- Publication number
- JPWO2019146673A1 JPWO2019146673A1 JP2019567132A JP2019567132A JPWO2019146673A1 JP WO2019146673 A1 JPWO2019146673 A1 JP WO2019146673A1 JP 2019567132 A JP2019567132 A JP 2019567132A JP 2019567132 A JP2019567132 A JP 2019567132A JP WO2019146673 A1 JPWO2019146673 A1 JP WO2019146673A1
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- lymphocytes
- iii
- seq
- fch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 159
- 238000012258 culturing Methods 0.000 claims abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 151
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 148
- 229920001184 polypeptide Polymers 0.000 claims description 146
- 150000001413 amino acids Chemical class 0.000 claims description 67
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 61
- 238000004519 manufacturing process Methods 0.000 claims description 57
- 238000004113 cell culture Methods 0.000 claims description 17
- 239000007790 solid phase Substances 0.000 claims description 13
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims description 10
- 239000011521 glass Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 abstract description 44
- 102000016359 Fibronectins Human genes 0.000 abstract description 44
- 239000012634 fragment Substances 0.000 abstract description 15
- 210000004027 cell Anatomy 0.000 description 96
- 235000001014 amino acid Nutrition 0.000 description 67
- 229940024606 amino acid Drugs 0.000 description 61
- 238000003780 insertion Methods 0.000 description 42
- 230000037431 insertion Effects 0.000 description 42
- 238000000034 method Methods 0.000 description 24
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 22
- 238000012217 deletion Methods 0.000 description 22
- 230000037430 deletion Effects 0.000 description 22
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 20
- 230000006870 function Effects 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 14
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 12
- 238000000576 coating method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 108091081024 Start codon Proteins 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 9
- 210000002443 helper t lymphocyte Anatomy 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108010056030 retronectin Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 108010041014 Integrin alpha5 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282564 Macaca fuscata Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003287 lymphocyte surface marker Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 206010052366 systemic mycosis Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/20—Material Coatings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Clinical Laboratory Science (AREA)
- Sustainable Development (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
[1]リンパ球を、
(a)ヒトフィブロネクチンのIII−1〜3リピートを含む組換えポリペプチド、もしくは前記のIII−1〜3リピートのアミノ酸配列において1もしくは数個のアミノ酸が置換、欠失、挿入もしくは付加されたアミノ酸配列を含む組換えポリペプチド、
(b)ヒトフィブロネクチンのIII−8〜10リピートを含む組換えポリペプチド、もしくは前記のIII−8〜10リピートのアミノ酸配列において1もしくは数個のアミノ酸が置換、欠失、挿入もしくは付加されたアミノ酸配列を含む組換えポリペプチド、及び
(c)ヒトフィブロネクチンのIII−12〜14リピートを含む組換えポリペプチド、もしくは前記のIII−12〜14リピートのアミノ酸配列において1もしくは数個のアミノ酸が置換、欠失、挿入もしくは付加されたアミノ酸配列を含む組換えポリペプチド、の存在下で培養する工程を包含する、リンパ球の製造方法、
[2]リンパ球を、(a)、(b)及び(c)の組換えポリペプチドを同一分子内に含む組換えポリペプチドの存在下で培養する工程を包含する、[1]に記載の製造方法、
[3]組換えポリペプチドが、配列番号19に記載のアミノ酸配列を含む組換えポリペプチドであるか、あるいは配列番号19に記載のアミノ酸配列において1もしくは数個のアミノ酸が置換、欠失、挿入もしくは付加されたアミノ酸配列を含む組換えポリペプチドである、[2]に記載の製造方法、
[4]組換えポリペプチドが、配列番号31に記載のアミノ酸配列を含む組換えポリペプチドであるか、あるいは配列番号31に記載のアミノ酸配列において1もしくは数個のアミノ酸が置換、欠失、挿入もしくは付加されたアミノ酸配列を含む組換えポリペプチドである、[2]に記載の製造方法、
[5]組換えポリペプチドと抗CD3抗体の共存下でリンパ球の培養が実施される、[1]〜[4]のいずれかに記載の製造方法、
[6]組換えポリペプチドの存在下でリンパ球を培養する工程が、組換えポリペプチドがコートされた固相とリンパ球とが接触した状態で実施される、[1]〜[5]のいずれかに記載の製造方法、
[7]固相が、細胞培養用器材又は細胞培養用担体である、[6]に記載の製造方法、
[8]固相が、ディッシュ、プレート、フラスコ、バッグ、ビーズ、メンブレン又はスライドガラスである、[6]に記載の製造方法、
[9]リンパ球が、ヒト由来のリンパ球である、[1]〜[8]のいずれかに記載の製造方法、
に関する。
<フィブロネクチン>
ヒト由来や哺乳動物由来のフィブロネクチンがよく研究されており、以下は、主にヒト由来血漿フィブロネクチンについての知見である。
本発明のリンパ球の製造方法は、リンパ球を組換えフィブロネクチンフラグメントであるポリペプチドの存在下で培養する工程を包含することを特徴とする。本明細書においてリンパ球とはリンパ球を含有する細胞集団を意味する。
メチオニン残基及び6個のヒスチジン残基から成るHis−tagをN末に有するFCH−296ポリペプチド(配列番号20)を、以下の操作により調製した。
以下の実施例で使用する培養器材に、抗ヒトCD3抗体(OKT3、タカラバイオ社製)及び実施例1で調製したHis−tag付きFCH−296を固定化した。固定化は24穴細胞培養プレート(ファルコン社製)に終濃度5μg/mLの抗ヒトCD3抗体と終濃度25μg/mLの上記His−tag付きFCH−296とを含むD−PBS(Promocell社製、C−40232)を0.4mL/ウェルずつ添加した後、37℃、5%CO2インキュベーターにて5時間以上静置して実施した。固定化プレートは使用直前に溶液を除去し、0.5mL/ウェルのD−PBSで2回洗浄した。また、対照として終濃度25μg/mLのCH−296(レトロネクチン:タカラバイオ社製)と終濃度5μg/mLの抗ヒトCD3抗体とを含むD−PBSでコートされたプレートも同様の方法で調製した。陰性対照にはコーティングをしていないプレートを用いた。
(1)細胞集団の拡大培養
インフォームド・コンセントの得られた健常人ドナー(TC0033)から常法に従い調製したヒト末梢血単核細胞(PBMC)を、終濃度200IU/mL IL−2(Proleukin、ニプロ社製)を添加したGT−T551培地(タカラバイオ社製、以下、GT−T551CMと称す)に1×105cells/mLになるように懸濁した。上記細胞を、2.8×105cells/ウェルでプレートにN=2で播種し、37℃、5%CO2で培養した(0日目)。
実施例3−(1)で得られた10日目の細胞集団を、0.1%ウシ血清アルブミン(シグマ社製)を含むPBS(以下、0.1%BSA/PBSと記載)で洗浄した。0.1%BSA/PBSに細胞集団を懸濁し、FITC標識マウス抗ヒトCD8抗体、RD−1標識マウス抗ヒトCD4抗体、PC−5標識マウス抗ヒトCD3抗体のカクテル抗体(ベックマンコールター社製)を添加し抗体反応を行った。その後、0.1%BSA/PBSで細胞集団を2回洗浄し、再度0.1%BSA/PBSに懸濁した。この細胞集団をフローサイトメトリー(FC−500、ベックマンコールター社製)に供し、各々の細胞集団のCD3陽性かつCD4陽性の細胞(CD3+CD4+)率を算出した。細胞表面マーカー測定の結果を表2に示す。なお、全細胞中のCD3陽性率はすべての試験区で94%以上であった。
(1)細胞集団の拡大培養
実施例3と同じ健常人ドナー(TC0033)及び異なる健常人ドナー(TC0071)から調製したPBMCを用いて、実施例3−(1)と同様の方法で細胞培養を行った。0日目の細胞数を1としたときの、4日目、7日目、及び10日目の細胞数を表3に示す。
実施例4−(1)で得られた10日目の細胞集団の細胞表面マーカーを、実施例3−(2)と同様の方法で測定した。結果を表4に示す。なお、全細胞中のCD3陽性率はすべての試験区で94%以上であった。
(1)細胞集団の拡大培養
健常人ドナー(TC0033及びTC0071)から調製したPBMCを、終濃度200IU/mL IL−2を添加したGT−T551CMに1×105cells/mLになるように懸濁した。上記細胞を、2.8×105cells/ウェルでプレートにN=2で播種し、37℃、5%CO2で培養した(0日目)。0日〜4日目までの培養には、抗ヒトCD3抗体と、FCH−296ポリペプチド(His−tag付き、配列番号20)又は9アミノ酸をN末に挿入したFCH−296ポリペプチド(配列番号31)をコーティングしたプレートを用いた。細胞継代は4日目及び7日目に行った。4日目には、コーティングをしていない12穴細胞培養プレートに2.612mL/ウェルのGT−T551CMと0.358mL/ウェルの細胞懸濁液を混合して培養を継続した。7日目には、コーティングをしていない12穴細胞培養プレートに1.485mL/ウェルのGT−T551CMと1.485mL/ウェルの細胞懸濁液を混合して培養を継続した。陰性対照には、培養0日目から、コーティングをしていないプレートを用いた。なお、9アミノ酸をN末に挿入したFCH−296ポリペプチドは、SP Sepharose(登録商標) Fast Flow(GE Healthcare社製)等の通常のカラムを用いて常法により調製した。
10日目の細胞集団の細胞表面マーカーを、実施例3−(2)と同様の方法で測定した。結果を表5に示す。なお、全細胞中のCD3陽性率はすべての試験区で94%以上であった。
実施例5−(1)で得られた10日目の細胞集団を、0.1%ウシ血清アルブミン(シグマ社製)を含むPBS(以下、0.1%BSA/PBSと記載)で洗浄した。0.1%BSA/PBSに細胞集団を懸濁し、RD−1標識IgG1マウス抗ヒト2H4(CD45RA)抗体(ベックマンコールター社製)及びFITC標識IgG2Aマウス抗ヒトCCR7抗体(R&D社製)、を添加し抗体反応を行った。その後、0.1%BSA/PBSで細胞集団を2回洗浄し、再度0.1%BSA/PBSに懸濁した。この細胞集団をフローサイトメトリーに供し、各々の細胞集団のナイーブ細胞比率(CD45RA+CCR7+)を算出した。測定の結果を図2に示す。
様々なN末配列をもつFCH−296を調製した。すなわち、N末9アミノ酸欠失のFCH−296(配列番号25)、N末6アミノ酸欠失のFCH−296(配列番号26)、N末5アミノ酸欠失のFCH−296(配列番号27)、N末3アミノ酸欠失のFCH−296(配列番号28)、FCH−296(配列番号19)、N末3アミノ酸挿入のFCH−296(配列番号29)、N末6アミノ酸挿入のFCH−296(配列番号30)、N末11アミノ酸挿入のFCH−296(配列番号32)、N末12アミノ酸挿入のFCH−296(配列番号33)、N末14アミノ酸挿入のFCH−296(配列番号34)、N末15アミノ酸挿入のFCH−296(配列番号35)、N末HKRHEEGH挿入のFCH−296(配列番号36)、N末HKRH挿入のFCH−296(配列番号37)、N末HH挿入のFCH−296(配列番号38)、及びN末HHH挿入のFCH−296(配列番号39)を調製した。
SEQ ID NO:2 ; Partial region of fibronectin named III-2
SEQ ID NO:3 ; Partial region of fibronectin named III-3
SEQ ID NO:4 ; Partial region of fibronectin named III-4
SEQ ID NO:5 ; Partial region of fibronectin named III-5
SEQ ID NO:6 ; Partial region of fibronectin named III-6
SEQ ID NO:7 ; Partial region of fibronectin named III-7
SEQ ID NO:8 ; Partial region of fibronectin named III-8
SEQ ID NO:9 ; Partial region of fibronectin named III-9
SEQ ID NO:10 ; Partial region of fibronectin named III-10
SEQ ID NO:11 ; Partial region of fibronectin named III-11
SEQ ID NO:12 ; Partial region of fibronectin named III-12
SEQ ID NO:13 ; Partial region of fibronectin named III-13
SEQ ID NO:14 ; Partial region of fibronectin named III-14
SEQ ID NO:15 ; Partial region of fibronectin named CS-1
SEQ ID NO:16 ; Fibronectin fragment named 120k-fr
SEQ ID NO:17 ; Fibronectin fragment named CH-271
SEQ ID NO:18 ; Fibronectin fragment named CH-296 (RetroNectin)
SEQ ID NO:19 ; Fibronectin fragment named FCH-296
SEQ ID NO:20 ; His-tag FCH-296
SEQ ID NO:21 ; N-terminal 9a.a. deletion of III-1
SEQ ID NO:22 ; N-terminal 6a.a. deletion of III-1
SEQ ID NO:23 ; N-terminal 5a.a. deletion of III-1
SEQ ID NO:24 ; N-terminal 3a.a. deletion of III-1
SEQ ID NO:25 ; N-terminal 9a.a. deletion of FCH-296
SEQ ID NO:26 ; N-terminal 6a.a. deletion of FCH-296
SEQ ID NO:27 ; N-terminal 5a.a. deletion of FCH-296
SEQ ID NO:28 ; N-terminal 3a.a. deletion of FCH-296
SEQ ID NO:29 ; N-terminal 3a.a. insertion of FCH-296
SEQ ID NO:30 ; N-terminal 6a.a. insertion of FCH-296
SEQ ID NO:31 ; N-terminal 9a.a. insertion of FCH-296
SEQ ID NO:32 ; N-terminal 11a.a. insertion of FCH-296
SEQ ID NO:33 ; N-terminal 12a.a. insertion of FCH-296
SEQ ID NO:34 ; N-terminal 14a.a. insertion of FCH-296
SEQ ID NO:35 ; N-terminal 15a.a. insertion of FCH-296
SEQ ID NO:36 ; N-terminal HKRHEEGH insertion of FCH-296
SEQ ID NO:37 ; N-terminal HKRH insertion of FCH-296
SEQ ID NO:38 ; N-terminal HH insertion of FCH-296
SEQ ID NO:39 ; N-terminal HHH insertion of FCH-296
Claims (9)
- リンパ球を、
(a)ヒトフィブロネクチンのIII−1〜3リピートを含む組換えポリペプチド、もしくは前記のIII−1〜3リピートのアミノ酸配列において1もしくは数個のアミノ酸が置換、欠失、挿入もしくは付加されたアミノ酸配列を含む組換えポリペプチド、
(b)ヒトフィブロネクチンのIII−8〜10リピートを含む組換えポリペプチド、もしくは前記のIII−8〜10リピートのアミノ酸配列において1もしくは数個のアミノ酸が置換、欠失、挿入もしくは付加されたアミノ酸配列を含む組換えポリペプチド、及び
(c)ヒトフィブロネクチンのIII−12〜14リピートを含む組換えポリペプチド、もしくは前記のIII−12〜14リピートのアミノ酸配列において1もしくは数個のアミノ酸が置換、欠失、挿入もしくは付加されたアミノ酸配列を含む組換えポリペプチド、の存在下で培養する工程を包含する、リンパ球の製造方法。 - リンパ球を、(a)、(b)及び(c)の組換えポリペプチドを同一分子内に含む組換えポリペプチドの存在下で培養する工程を包含する、請求項1に記載の製造方法。
- 組換えポリペプチドが、配列番号19に記載のアミノ酸配列を含む組換えポリペプチドであるか、あるいは配列番号19に記載のアミノ酸配列において1もしくは数個のアミノ酸が置換、欠失、挿入もしくは付加されたアミノ酸配列を含む組換えポリペプチドである、請求項2に記載の製造方法。
- 組換えポリペプチドが、配列番号31に記載のアミノ酸配列を含む組換えポリペプチドであるか、あるいは配列番号31に記載のアミノ酸配列において1もしくは数個のアミノ酸が置換、欠失、挿入もしくは付加されたアミノ酸配列を含む組換えポリペプチドである、請求項2に記載の製造方法。
- 組換えポリペプチドと抗CD3抗体の共存下でリンパ球の培養が実施される、請求項1〜4のいずれか1項に記載の製造方法。
- 組換えポリペプチドの存在下でリンパ球を培養する工程が、組換えポリペプチドがコートされた固相とリンパ球とが接触した状態で実施される、請求項1〜5のいずれか1項に記載の製造方法。
- 固相が、細胞培養用器材又は細胞培養用担体である、請求項6に記載の製造方法。
- 固相が、ディッシュ、プレート、フラスコ、バッグ、ビーズ、メンブレン又はスライドガラスである、請求項6に記載の製造方法。
- リンパ球が、ヒト由来のリンパ球である、請求項1〜8のいずれか1項に記載の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018010494 | 2018-01-25 | ||
JP2018010494 | 2018-01-25 | ||
PCT/JP2019/002202 WO2019146673A1 (ja) | 2018-01-25 | 2019-01-24 | リンパ球の製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2019146673A1 true JPWO2019146673A1 (ja) | 2021-01-07 |
JP7173994B2 JP7173994B2 (ja) | 2022-11-17 |
Family
ID=67394990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019567132A Active JP7173994B2 (ja) | 2018-01-25 | 2019-01-24 | リンパ球の製造方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210062141A1 (ja) |
EP (1) | EP3744832A4 (ja) |
JP (1) | JP7173994B2 (ja) |
KR (1) | KR20200112868A (ja) |
CN (1) | CN111655842B (ja) |
WO (1) | WO2019146673A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024023245A1 (en) * | 2022-07-27 | 2024-02-01 | Biocell Innovations Pte. Ltd. | Production of cells and viral vectors |
CN116589560B (zh) * | 2023-05-10 | 2024-01-05 | 山西锦波生物医药股份有限公司 | 生物合成重组人源化纤连蛋白以及制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007020880A1 (ja) * | 2005-08-17 | 2007-02-22 | Takara Bio Inc. | リンパ球の製造方法 |
WO2007142300A1 (ja) * | 2006-06-09 | 2007-12-13 | Takara Bio Inc. | リンパ球の製造方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6472204B1 (en) | 1995-11-13 | 2002-10-29 | Kiyozo Asada | Methods for retroviral mediated gene transfer employing molecules, or mixtures thereof, containing retroviral binding domains and target cell binding domains |
AU8780198A (en) | 1998-08-11 | 2000-03-06 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | A method of transducing mammalian cells, and products related thereto |
WO2003080817A1 (en) * | 2002-03-25 | 2003-10-02 | Takara Bio Inc. | Process for producing cytotoxic lymphocyte |
KR20060039940A (ko) | 2003-08-22 | 2006-05-09 | 다카라 바이오 가부시키가이샤 | 세포 상해성 림프구의 제조 방법 |
CA2624900A1 (en) * | 2005-10-04 | 2007-04-19 | The Research Foundation Of State University Of New York | Fibronectin polypeptides and methods of use |
CN102597223B (zh) * | 2009-09-11 | 2017-05-10 | 宝生物工程株式会社 | 生产天然杀伤细胞的方法 |
US20180371413A1 (en) * | 2015-08-28 | 2018-12-27 | Ctm@Crc Ltd. | Products and methods for activating and/or expanding t cells |
KR20190033568A (ko) * | 2016-07-29 | 2019-03-29 | 다카라 바이오 가부시키가이샤 | 줄기세포의 제조에 사용되는 피브로넥틴 프래그먼트 |
-
2019
- 2019-01-24 EP EP19744513.3A patent/EP3744832A4/en active Pending
- 2019-01-24 JP JP2019567132A patent/JP7173994B2/ja active Active
- 2019-01-24 CN CN201980010078.2A patent/CN111655842B/zh active Active
- 2019-01-24 WO PCT/JP2019/002202 patent/WO2019146673A1/ja unknown
- 2019-01-24 KR KR1020207022378A patent/KR20200112868A/ko not_active Application Discontinuation
- 2019-01-24 US US16/961,773 patent/US20210062141A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007020880A1 (ja) * | 2005-08-17 | 2007-02-22 | Takara Bio Inc. | リンパ球の製造方法 |
WO2007142300A1 (ja) * | 2006-06-09 | 2007-12-13 | Takara Bio Inc. | リンパ球の製造方法 |
Non-Patent Citations (4)
Title |
---|
BIOTHERAPY, vol. 22, no. 5, JPN6022029339, September 2008 (2008-09-01), pages 297 - 302, ISSN: 0004827689 * |
BRITISH JOURNAL OF CANCER, vol. 74, JPN7022003310, 1996, pages 1598 - 1604, ISSN: 0004827690 * |
CELLULAR IMMUNOLOGY, vol. 135, JPN6022029338, 1991, pages 105 - 117, ISSN: 0004827688 * |
和歌山医学, vol. 46, no. 4, JPN6022029337, 1995, pages 457 - 467, ISSN: 0004827687 * |
Also Published As
Publication number | Publication date |
---|---|
EP3744832A4 (en) | 2021-11-24 |
KR20200112868A (ko) | 2020-10-05 |
EP3744832A1 (en) | 2020-12-02 |
US20210062141A1 (en) | 2021-03-04 |
JP7173994B2 (ja) | 2022-11-17 |
WO2019146673A1 (ja) | 2019-08-01 |
CN111655842A (zh) | 2020-09-11 |
CN111655842B (zh) | 2023-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5156382B2 (ja) | T細胞集団の製造方法 | |
JP4929174B2 (ja) | リンパ球の製造方法 | |
JP4406566B2 (ja) | 細胞傷害性リンパ球の製造方法 | |
JP7023228B2 (ja) | 幹細胞の製造に用いられるフィブロネクチンフラグメント | |
KR100858857B1 (ko) | 항원특이적 세포상해성 t 세포 확대배양방법 | |
JP4870432B2 (ja) | 細胞傷害性リンパ球の製造方法 | |
JP7173994B2 (ja) | リンパ球の製造方法 | |
JP2013176403A (ja) | γδT細胞集団の製造方法 | |
JPWO2007142300A1 (ja) | リンパ球の製造方法 | |
JP4741906B2 (ja) | リンパ球の製造方法 | |
JP2010099022A (ja) | リンパ球の製造方法 | |
MX2008004225A (es) | Metodo para la produccion de una poblacion de celulas t | |
JP2010094123A (ja) | リンパ球の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210816 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220912 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221011 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221104 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7173994 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |